Cardinal Health reports mixed quarterly performance across its business segments as earnings get a lift from one-time tariff refunds.
Cardinal Health heads into Q4 earnings with pharma, specialty and higher-margin businesses in focus as investors watch if growth offsets pricing headwinds.
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Cardinal (CAH) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Beyond analysts' top-and-bottom-line estimates for Cardinal (CAH), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended June 2026.
Cardinal (CAH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Cardinal Health (CAH) closed the most recent trading day at $235.6, moving +2.42% from the previous trading session.
Cardinal (CAH) is well positioned to outperform the market, as it exhibits above-average growth in financials.
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
In the most recent trading session, Cardinal Health (CAH) closed at $232.51, indicating a +1.38% shift from the previous trading day.